Rep. Pete Sessions (R-TX) Sells AbbVie (ABBV) Stock
Rep. Pete Sessions reported a sale of AbbVie shares valued between $15,001 and $50,000.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Pete Sessions (R-TX) sold between $15,001 and $50,000 of AbbVie Inc. ($ABBV) stock on September 14, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed September 18, 2026.
Since the trade, $ABBV is up 1.0% after 1 week, up 8.3% after 1 month and up 9.7% to date (from the $260.17 close on Sep 14, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Pete Sessions (R-TX)
- Status:
- Member — House
- State/District:
- TX-17
- Party:
- Republican
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Sep 18, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| AbbVie Inc. ($ABBV) | Sell | Sep 14, 2026 | $15,001 - $50,000 |
Summary of the filed report, not the original document. Find the original: House financial disclosure search
ABBV
AbbVie Inc.
Key Points
- Pete Sessions sold shares of AbbVie Inc. valued between $15,001 and $50,000 on September 14, 2026.
- AbbVie shares closed at $285.52 on the day of the sale, after having traded near its 52-week high of $267.47.
- AbbVie Inc. has an analyst consensus recommending a 'buy' with a mean price target of $278.61.
Get $ABBV trade alerts by text
We text you when insiders, Congress or big funds trade $ABBV. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated AbbVie Inc. alert may contain errors. Disclosures
Rep. Pete Sessions, a Republican member of the House from Texas, reported selling shares of AbbVie Inc. (NYSE: ABBV) on September 14, 2026. The sale was valued between $15,001 and $50,000, according to disclosures made on September 18, 2026. On that day, AbbVie shares were trading at $285.52, reflecting strong performance amid recent market activity.
Pete Sessions vs. the S&P 500
Hypothetical returns from Pete Sessions's disclosed trades, not real profit or advice. How we model this.
Inside Pete Sessions' Trade
Pete Sessions sold his shares of AbbVie in a transaction reported under the STOCK Act. This move follows his prior sale of Apple Inc. shares valued between $100,001 and $250,000 on September 22, 2026, showing that Sessions is actively managing his investment portfolio.
Other Institutional Activity in AbbVie
Several institutional investors have recently adjusted their positions in AbbVie. Blackrock Inc. trimmed its stake by 1,205,552 shares, ending with 149,488,412 shares valued at approximately $42.68 billion. Vanguard Capital Management LLC added 516,956 shares, growing its holdings to 115,396,098 shares worth around $32.95 billion. State Street Corporation increased its position by 1,380,673 shares, now holding 82,596,748 shares valued at about $23.58 billion.
AbbVie Inc. Stock Up 0.7%
AbbVie shares are currently trading above their 50-day moving average of $255.68 and not far from the 52-week high of $267.47. The stock's recent price movement suggests investor interest remains strong. The company has a market capitalization of approximately $467.37 billion.
Recent Earnings
In its most recent earnings report, AbbVie posted revenue of about $64.39 billion, reflecting a revenue growth of 10.2%. The company achieved an earnings per share (EPS) of $3.54, with a net margin of 9.8%. AbbVie is set to announce its next earnings on October 29, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
4 analysts raised price targets.
-
EPS & revenue
EPS met estimates. Revenue met estimates.
-
Profit surprise
EBITDA missed by 42 percent. Operating income missed by 72 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
4 target raises.
-
Earnings quality
Gross margin up 1.9 points. Operating margin up 3.6 points. Positive free cash flow.
Earnings Call Summary
AbbVie delivered strong first quarter results with $15 billion in sales and earnings per share of $2.65, beating expectations. Skyrizi sales hit $4.5 billion with 29 percent growth in psoriasis and inflammatory bowel disease markets. Rinvoq brought in $2.1 billion with 20 percent growth across rheumatology and gastroenterology, and the company is preparing to launch the drug in alopecia areata and vitiligo later this year.
Guidance The company raised full year earnings per share guidance to between $14.08 and $14.28, up $0.12. They now expect about $67.3 billion in total sales for the year. They also raised guidance for second quarter to about $16.7 billion in revenue and earnings per share between $3.74 and $3.78.
Fine but not compelling. Acceptable results that likely do not create a meaningful forward reset.
Analysts Set New Price Targets
Analysts have recently expressed confidence in AbbVie, with RBC Capital reiterating an "Outperform" rating and a price target of $280.00 on October 13, 2026. UBS maintained a "Neutral" rating with a target of $275.00 on October 9, 2026. Overall, the mean target price among analysts stands at $278.61 based on 28 opinions, showing a general positive outlook for the stock.
About AbbVie
AbbVie Inc. is a North Chicago-based biopharmaceutical company dedicated to the research, development, and sale of various medicines and therapies. The company is involved in producing treatments for complex diseases, including autoimmune conditions and various cancers. This recent trade by Rep. Sessions draws attention to AbbVie's ongoing presence in the healthcare sector.
Bottom Line
Investors should keep an eye on AbbVie's upcoming earnings report on October 29, 2026, as it may provide further insight into the company's performance and market position. As this is a retrospective disclosure, it reflects Sessions' position as of September 14, 2026, and may not indicate his current holdings.
Related Filing Alerts
Source: Pete Sessions's STOCK Act disclosure on $ABBV (Sep 14, 2026). Find the original filing: House financial disclosure search. Written by software, not financial advice. How we make alerts